Effectiveness of high-dose infliximab among patients previously treated with standard doses (5 to < 10 mg/kg) of infliximab.
| MD Global | Active Joint Count | |||||
|---|---|---|---|---|---|---|
| n | Median (range) | p* | n | Median (range) | p* | |
| Baseline | 15 | 20 (5–80) | NA | 15 | 2 (0–34) | NA |
| 3 months | 10 | 10 (2–35) | 0.021 | 10 | 0 (0–12) | 0.007 |
| 6 months | 7 | 10 (2–34) | 0.201 | 7 | 0 (0–2) | 0.093 |
| 12 months | 10 | 11 (2–31) | 0.05 | 10 | 0 (0–31) | 0.027 |
↵* p values are pairwise comparisons to patients with data at the indicated timepoint compared to baseline. Because of the exclusion of patients in whom the indication for infliximab therapy was uveitis, the number of subjects depicted in this table is lower than the total number of subjects in the study who had previously received standard doses of infliximab. MD global: physician global assessment of disease activity; NA: not applicable.